NCT01707043View on ClinicalTrials.gov

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2013

Conditions
Plaque Psoriasis
Interventions
DRUG

Taclonex

Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

Wake Forest University

OTHER